1
|
Frischknecht L, Schaab J, Schmauch E, Yalamanoglu A, Arnold DD, Schwaiger J, Gruner C, Buechel RR, Franzen DP, Kolios AG, Nilsson J. Assessment of treatment response in cardiac sarcoidosis based on myocardial 18F-FDG uptake. Front Immunol 2023; 14:1286684. [PMID: 38077350 PMCID: PMC10704456 DOI: 10.3389/fimmu.2023.1286684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Accepted: 11/08/2023] [Indexed: 12/18/2023] Open
Abstract
Objective Immunosuppressive therapy for cardiac sarcoidosis (CS) still largely consists of corticosteroid monotherapy. However, high relapse rates after tapering and insufficient efficacy are significant problems. The objective of this study was to investigate the efficacy and safety of non-biological and biological disease-modifying anti-rheumatic drugs (nb/bDMARDs) considering control of myocardial inflammation assessed by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) of the heart. Methods We conducted a retrospective analysis of treatment response to nb/bDMARDs of all CS patients seen in the sarcoidosis center of the University Hospital Zurich between January 2016 and December 2020. Results We identified 50 patients with CS. Forty-five patients with at least one follow-up PET/CT scan were followed up for a mean of 20.5 ± 12.8 months. Most of the patients were treated with prednisone and concomitant nb/bDMARDs. At the first follow-up PET/CT scan after approximately 6.7 ± 3 months, only adalimumab showed a significant reduction in cardiac metabolic activity. Furthermore, comparing all serial follow-up PET/CT scans (143), tumor necrosis factor inhibitor (TNFi)-based therapies showed statistically significant better suppression of myocardial 18F-FDG uptake compared to other treatment regimens. On the last follow-up, most adalimumab-treated patients were inactive (n = 15, 48%) or remitting (n = 11, 35%), and only five patients (16%) were progressive. TNFi was safe even in patients with severely reduced left ventricular ejection fraction (LVEF), and a significant improvement in LVEF under TNFi treatment was observed. Conclusion TNFi shows better control of myocardial inflammation compared to nbDMARDs and corticosteroid monotherapies in patients with CS. TNFi was efficient and safe even in patients with severely reduced LVEF.
Collapse
Affiliation(s)
- Lukas Frischknecht
- Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland
| | - Jan Schaab
- Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Zurich, Switzerland
| | - Eloi Schmauch
- Broad Institute of MIT and Harvard, Cambridge, MA, United States
- Artturi Ilmari (A.I) Virtanen Institute, University of Eastern Finland, Kuopio, Finland
- Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States
| | - Ayla Yalamanoglu
- Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland
| | - Dennis D. Arnold
- Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland
| | - Judith Schwaiger
- Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
| | - Christiane Gruner
- Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
| | - Ronny R. Buechel
- Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Zurich, Switzerland
| | - Daniel P. Franzen
- Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland
| | - Antonios G.A. Kolios
- Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| | - Jakob Nilsson
- Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland
| |
Collapse
|
2
|
Jungo P, Maul JT, Djamei V, von Felten S, Kolios AG, Czernielewsk J, Yawalkar N, Odermatt O, Laffitte E, Anliker M, Streit M, Augustin M, Conrad C, Hafner J, Boehncke WH, Gilliet M, Itin P, French LE, Navarini AA, Häusermann P. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. Dermatology 2017; 232:655-663. [DOI: 10.1159/000455042] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Accepted: 12/08/2016] [Indexed: 11/19/2022] Open
|
3
|
Maul JT, Djamei V, Kolios AG, Meier B, Czernielewski J, Jungo P, Yawalkar N, Mainetti C, Laffitte E, Spehr C, Anliker M, Streit M, Augustin M, Rustenbach S, Conrad C, Hafner J, Boehncke WH, Borradori L, Gilliet M, Itin P, French LE, Häusermann P, Navarini AA. Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. Dermatology 2017; 232:640-647. [DOI: 10.1159/000452740] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Accepted: 10/03/2016] [Indexed: 11/19/2022] Open
|
4
|
Abstract
Apremilast is an oral phosphodiesterase IV inhibitor recently registered for the treatment of psoriasis and psoriatic arthritis in Switzerland and other countries. Even though it offers only moderate efficacy compared to biologics, many patients prefer drugs given by the oral route. Apremilast is frequently used in private practice, as it showed no relevant safety signals in clinical trials and often, laboratory tests are omitted completely. Here we report a patient who developed acute lymphopenia and worsening of psoriasis during apremilast treatment, which resolved with discontinuation of apremilast. We suggest that at least in prospective registries, that regular monitoring of laboratory surrogate markers should be performed on a long-term basis to detect rare but potentially important safety signals.
Collapse
Affiliation(s)
- Antonios G.A. Kolios
- Department of Immunology, Zurich University Hospital, Zurich, Switzerland
- Department of Dermatology, Zurich University Hospital, Zurich, Switzerland
- *Dr. med. Antonios G.A. Kolios, Department of Immunology and Dermatology, University Hospital Zurich, Gloriastrasse 23, CH-8091 Zurich (Switzerland), E-Mail
| | - Lars E. French
- Department of Dermatology, Zurich University Hospital, Zurich, Switzerland
| | | |
Collapse
|
5
|
Kolios AG, Yawalkar N, Anliker M, Boehncke WH, Borradori L, Conrad C, Gilliet M, Häusermann P, Itin P, Laffitte E, Mainetti C, French LE, Navarini AA. Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology 2016; 232:385-406. [DOI: 10.1159/000445681] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2016] [Accepted: 03/20/2016] [Indexed: 11/19/2022] Open
|
6
|
Navarini AA, Muster MA, Kolios AG, Fritsche P, Glatz M, French LE, Trüeb RM. Weight-Based Adaptation of TNF-Antagonist Induction versus Maintenance Dose. Case Rep Dermatol 2011; 3:124-9. [PMID: 21734878 PMCID: PMC3128133 DOI: 10.1159/000329343] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
Biologics are highly specific and exhibit few problems in regard to overdosages. In clinical practice, induction schemes with an initial loading dose and a subsequent lower maintenance dose have been established and are of higher efficacy for psoriasis than starting directly with the maintenance dose. As obese patients sometimes respond less well to standard dosages, increases of the maintenance dose, but not the loading doses, have been tried with variable success. In our study, we increased the loading (160 mg instead of 80 mg) but not the maintenance dose of adalimumab in an obese patient with severe psoriasis resistant to previous biologics and methotrexate. Within 12 weeks, both PASI (11 to 1.6) and DLQI (22/30 to 5/30) decreased. This strategy might be an effective and less costly alternative to doubling the maintenance doses, and could be further evaluated for psoriasis patients refractory to previous treatments.
Collapse
Affiliation(s)
- Alexander A. Navarini
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
- *Alexander A. Navarini, Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH-8091 Zurich (Switzerland), Tel. +41 44 255 1111, E-Mail
| | - Marco A. Muster
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
| | | | - Philipp Fritsche
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
| | - Martin Glatz
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
| | - Lars E. French
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
| | - Ralph M. Trüeb
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
- Skin and Hair Center Professor Trüeb, Wallisellen, Switzerland
| |
Collapse
|